Lack of a significant legacy effect of baseline blood pressure 'treatment naivety' on all-cause and cardiovascular mortality in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial

被引:0
作者
Ho, Chau L. B. [1 ]
Breslin, Monique [1 ]
Chowdhury, Enayet K. [2 ,3 ]
Doust, Jenny [4 ]
Reid, Christopher M. [2 ,3 ]
Davis, Barry R. [5 ]
Simpson, Lara M. [5 ]
Nelson, Mark R. [1 ,3 ]
机构
[1] Univ Tasmania, Menzies Inst Med Res, Private Bag 23, Hobart, Tas 7001, Australia
[2] Curtin Univ, Sch Publ Hlth, Perth, WA, Australia
[3] Monash Univ, Sch Publ Hlth & Prevent Med, CCRE Therapeut, Melbourne, Vic, Australia
[4] Bond Univ, Ctr Res Evidence Based Practice, Gold Coast, Qld, Australia
[5] Univ Texas Houston, Sch Publ Hlth, Houston, TX USA
基金
英国惠康基金; 美国国家卫生研究院;
关键词
absolute cardiovascular risk; all-cause mortality; antihypertensive drug; cardiovascular disease; cardiovascular disease mortality; hypertension; primary prevention; HYPERTENSION; RISK; PRAVASTATIN; FOSINOPRIL; DISEASE; EVENTS; ADULTS; END;
D O I
10.1097/HJH.0000000000002280
中图分类号
R6 [外科学];
学科分类号
1002 ; 100210 ;
摘要
Objectives: To investigate legacy effects at 14-year follow-up of all-cause and cardiovascular disease (CVD) mortality in 'treatment-naive' or 'previous treatment' groups based on blood pressure (BP)-lowering treatment status at baseline. Methods: A post-hoc observational study of the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. We excluded participants with a previous history of CVD events. Cox proportional hazard model and 95% confidence interval were used to estimate the effects of treatment naive on mortality outcomes. Moreover, a subgroup analysis by estimated 10-year Framingham risk score was performed. Results: In multivariable models adjusting for baseline and in-trial characteristics (BP values and number of BP medications as time-dependent variables), there was no statistically significant difference in 5 and 14-year all-cause mortality with a hazard ratio of 0.93 (95% confidence interval 0.80-1.09) and hazard ratio 0.95 (0.88-1.03) and in 5 and 14-year CVD mortality hazard ratio 0.94 (0.72-1.23) and hazard ratio 0.93 (0.80-1.08). In subgroup by absolute CVD risk, no heterogeneity of the association between treatment naive and short-term or long-term all-cause or CVD mortality were found. All comparisons are between the treatment-naive and previous treatment groups. Conclusion: Physicians are concerned about 'legacy effects' of not treating individuals with a BP of 140 mmHg or over and low absolute risk. When treatment intensification was taken into consideration in the primary prevention population in this study, no adverse legacy effect as a result of baseline BP 'treatment naivety' was evident in 14 years of follow-up. The nonsignificant associations were consistent across the CVD risk subgroups. However, the results may be biased due to unobserved residual confounding and therefore should be interpreted with caution.
引用
收藏
页码:519 / 526
页数:8
相关论文
共 20 条
[1]  
[Anonymous], 2018, CARD DIS RISK ASS MA
[2]  
[Anonymous], GUID MAN ABS CARD DI
[3]   Cardiovascular Risk With and Without Antihypertensive Drug Treatment in the Japanese General Population Participant-Level Meta-Analysis [J].
Asayama, Kei ;
Satoh, Michihiro ;
Murakami, Yoshitaka ;
Ohkubo, Takayoshi ;
Nagasawa, Sin-ya ;
Tsuji, Ichiro ;
Nakayama, Takeo ;
Okayama, Akira ;
Miura, Katsuyuki ;
Imai, Yutaka ;
Ueshima, Hirotsugu ;
Okamura, Tomonori .
HYPERTENSION, 2014, 63 (06) :1189-1197
[4]   Effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria [J].
Asselbergs, FW ;
Diercks, GFH ;
Hillege, HL ;
van Boven, AJ ;
Janssen, WMT ;
Voors, AA ;
de Zeeuw, D ;
de Jong, PE ;
van Veldhuisen, DJ ;
van Gilst, WH .
CIRCULATION, 2004, 110 (18) :2809-2816
[5]   Long-Term Effects of Incident Diabetes Mellitus on Cardiovascular Outcomes in People Treated for Hypertension The ALLHAT Diabetes Extension Study [J].
Barzilay, Joshua I. ;
Davis, Barry R. ;
Pressel, Sara L. ;
Cutler, Jeffrey A. ;
Einhorn, Paula T. ;
Black, Henry R. ;
Cushman, William C. ;
Ford, Charles E. ;
Margolis, Karen L. ;
Moloo, Jamaluddin ;
Oparil, Suzanne ;
Piller, Linda B. ;
Simmons, Debra L. ;
Sweeney, Mary Ellen ;
Whelton, Paul K. ;
Wong, Nathan D. ;
Wright, Jackson T., Jr. .
CIRCULATION-CARDIOVASCULAR QUALITY AND OUTCOMES, 2012, 5 (02) :153-U48
[6]   Residual cardiovascular risk in treated hypertension and hyperlipidaemia: the PRIME Study [J].
Blacher, J. ;
Evans, A. ;
Arveiler, D. ;
Amouyel, P. ;
Ferrieres, J. ;
Bingham, A. ;
Yarnell, J. ;
Haas, B. ;
Montaye, M. ;
Ruidavets, J-B ;
Ducimetiere, P. .
JOURNAL OF HUMAN HYPERTENSION, 2010, 24 (01) :19-26
[7]   Long-term effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria: Ten years of follow-up of Prevention of Renal and Vascular End-stage Disease Intervention Trial (PREVEND IT) [J].
Brouwers, Frank P. ;
Asselbergs, Folkert W. ;
Hillege, Hans L. ;
de Boer, Rudolf A. ;
Gansevoort, Ron T. ;
van Veldhuisen, Dirk J. ;
van Gilst, Wiek H. .
AMERICAN HEART JOURNAL, 2011, 161 (06) :1171-1178
[8]   General cardiovascular risk profile for use in primary care - The Framingham Heart Study [J].
D'Agostino, Ralph B. ;
Vasan, Ramachandran S. ;
Pencina, Michael J. ;
Wolf, Philip A. ;
Cobain, Mark ;
Massaro, Joseph M. ;
Kannel, William B. .
CIRCULATION, 2008, 117 (06) :743-753
[9]   Joint British Societies' consensus recommendations for the prevention of cardiovascular disease (JBS3) [J].
Deanfield, John ;
Simpson, Iain ;
Bradbury, Kirsten ;
Fox, Keith ;
Boon, Nick ;
Winocour, Peter ;
Feher, Michael ;
Doherty, Patrick ;
Buckley, John ;
Jennings, Catriona ;
Keenan, Jan ;
Weissberg, Peter ;
Knapton, Mike ;
Williams, Bryan ;
Poulter, Neil ;
Stevens, Paul ;
Taal, Maarten ;
Grant, Peter ;
Home, Philip ;
Sattar, Naveed ;
Rees, Alan ;
Neely, Dermot ;
Wheeler, David ;
Goldsmith, David ;
Potter, John ;
Jackson, Stephen .
HEART, 2014, 100 :1-67
[10]  
Furberg CD, 2002, JAMA-J AM MED ASSOC, V288, P2981